Alprostadil (Caverject/MUSE) and Sildenafil Interaction

Why This Combination Raises Concern

Both alprostadil and sildenafil lower vascular resistance through distinct but converging pathways, and the result is an additive drop in blood pressure that can become clinically significant. Alprostadil is a synthetic prostaglandin E1 (PGE1) that directly relaxes smooth muscle in the corpus cavernosum and systemic vasculature by increasing intracellular cyclic AMP (cAMP) [1]. Sildenafil inhibits phosphodiesterase type 5 (PDE5), preventing the breakdown of cyclic GMP (cGMP) in penile smooth muscle and the pulmonary and systemic vasculature [2].

The key distinction: these two drugs act on parallel but separate second-messenger systems. Alprostadil raises cAMP. Sildenafil raises cGMP. Both second messengers cause smooth muscle relaxation and vasodilation independently. When present at elevated levels simultaneously, the vasodilatory effect does not simply add up arithmetically. It compounds. The corpus cavernosum receives a dual relaxation signal, increasing both the efficacy of the erectile response and the risk of priapism. The systemic vasculature receives the same dual signal, producing blood pressure reductions that exceed what either drug causes alone [3].

This is not a cytochrome P450 or P-glycoprotein interaction. Sildenafil is metabolized primarily by CYP3A4 and to a lesser extent CYP2C9 [2]. Alprostadil undergoes rapid pulmonary first-pass metabolism (approximately 80% cleared in a single pass through the lungs) via beta-oxidation and omega-oxidation, entirely independent of hepatic CYP enzymes [1]. The two drugs do not compete for the same metabolic pathways or transport proteins. The interaction is purely pharmacodynamic.

What the FDA Labels Say

The Caverject (alprostadil for injection) prescribing information states that the drug should not be used in combination with other vasoactive agents administered intracavernosally, and it warns that the concomitant use of systemic vasoactive medications may increase the risk of hypotension [1]. The MUSE (alprostadil urethral suppository) label carries a similar warning, specifying that patients using antihypertensives or other vasoactive medications may experience additive blood pressure effects [4].

The Viagra (sildenafil) prescribing information does not specifically name alprostadil, but it warns broadly against "combination with other treatments for erectile dysfunction" and notes that the safety and efficacy of sildenafil combined with other PDE5 inhibitors or other treatments for ED, including intracavernosal injection therapies, have not been studied [2]. The label is clear that sildenafil potentiates the hypotensive effects of nitrates and other vasodilators.

All three major drug interaction databases (Lexicomp, Micromedex, and Clinical Pharmacology) classify this interaction as "major" or "contraindicated," recommending avoidance unless the potential benefit clearly outweighs the risk under specialist care [5].

Severity: How Dangerous Is the Combination?

The risk is real but context-dependent. A 2002 study by Mydlo and colleagues published in Urology examined 20 patients with refractory ED who had failed both sildenafil monotherapy and intracavernosal alprostadil monotherapy. When the two agents were combined (sildenafil 50 mg orally followed by intracavernosal alprostadil 10-20 mcg), 15 of 20 patients (75%) achieved erections sufficient for intercourse. Two patients experienced symptomatic hypotension requiring supine positioning and IV fluids. No episodes of priapism occurred in this small series [6].

A separate case series by McMahon (2002) in the International Journal of Impotence Research reported on 57 patients using combination PDE5 inhibitor plus intracavernosal injection therapy. Systolic blood pressure fell by a mean of 18 mmHg within 60 minutes of combined dosing. Three patients (5.3%) had symptomatic orthostatic events. One patient developed a prolonged erection lasting 5 hours that resolved with phenylephrine injection [7].

These numbers paint a consistent picture. The combination works for many patients who have failed monotherapy. The blood pressure drop is predictable and usually manageable. But the tail risks (severe hypotension, priapism requiring emergency detumescence) are not trivial. A patient who combines these drugs without medical oversight and experiences a prolonged erection at home faces a genuine urological emergency.

Who Might Be Prescribed This Combination

Off-label combination use is typically reserved for a specific patient profile: men with severe, organic erectile dysfunction who have documented failure of both oral PDE5 inhibitor therapy at maximum tolerated doses and intracavernosal injection therapy at adequate doses. This population includes men who have undergone radical prostatectomy (nerve-sparing or non-nerve-sparing), men with severe diabetes-related vasculopathy, and men with Peyronie's disease affecting erectile function [8].

The American Urological Association (AUA) 2018 guideline on erectile dysfunction acknowledges combination therapy as a treatment option for refractory cases, noting that "combination of a PDE5i with intracavernosal injection or intraurethral alprostadil may be considered after appropriate counseling regarding risks" [9]. The European Association of Urology (EAU) 2024 guideline similarly recognizes combination approaches for non-responders, recommending that such combinations be initiated and monitored in a specialist setting [10].

Patients with the following characteristics are generally excluded from combination therapy:

• Resting systolic blood pressure <90 mmHg
• Active nitrate therapy (absolute contraindication for sildenafil regardless of alprostadil status)
• History of priapism or conditions predisposing to priapism (sickle cell disease, multiple myeloma, leukemia)
• Penile anatomical deformities that increase priapism risk (severe Peyronie's with significant curvature)
• Unstable cardiovascular disease or recent stroke/MI within 6 months

Dose Adjustments and Timing Protocols

When a specialist does prescribe this combination, the standard approach involves significant dose reductions for both agents. The general protocol documented in the literature follows a predictable pattern [6][7].

For sildenafil, the dose is typically reduced to 25 mg (the lowest commercially available tablet strength), taken orally 60 minutes before anticipated sexual activity. This is half the standard starting dose and one-quarter of the maximum single dose.

For alprostadil intracavernosal injection (Caverject), the dose is reduced to the lowest effective level, often starting at 2.5-5 mcg and titrating upward in 2.5 mcg increments only under office supervision. Standard monotherapy doses of 10-40 mcg are not appropriate starting points when combined with a PDE5 inhibitor.

For alprostadil urethral suppository (MUSE), a similar reduction applies. Starting at 125-250 mcg rather than the standard 500-1000 mcg range.

The timing question matters. Some prescribers recommend a full 24-hour separation between the two agents, meaning the patient uses one drug one day and the other drug the following day. Other specialists permit same-day use with a stagger: sildenafil taken orally first, followed by intracavernosal alprostadil 60-90 minutes later, so that peak plasma levels do not fully overlap [6]. Sildenafil reaches peak plasma concentration at approximately 60 minutes (range 30-120 minutes), and alprostadil produces peak intracavernosal effect within 5-20 minutes of injection [1][2].

The first combined dose should always occur in a clinical setting with blood pressure monitoring. Vital signs should be checked at baseline, at 30 minutes post-sildenafil, and at 15 and 30 minutes post-alprostadil administration.

Monitoring and Patient Counseling

Patients prescribed this combination need specific, actionable instructions. Blood pressure self-monitoring at home is strongly recommended. A simple automated cuff used before and after dosing gives the patient objective data. Any systolic reading below 90 mmHg or any drop exceeding 30 mmHg from baseline warrants lying down immediately and contacting the prescribing physician [3].

Priapism counseling is non-negotiable. Patients must understand that an erection lasting longer than 2 hours (not the commonly cited 4-hour threshold, which represents the point at which ischemic damage becomes increasingly likely) warrants an emergency department visit. The 4-hour mark on the sildenafil label is the point of definite emergency. The 2-hour mark is when a patient on combination therapy should begin taking action: applying ice, light exercise, and attempting ejaculation. If the erection persists past 3 hours, emergency aspiration and phenylephrine injection become necessary to prevent irreversible ischemic injury to the corpora cavernosa [11].

Alcohol should be avoided entirely when using this combination. Ethanol is a vasodilator that adds a third hypotensive mechanism to the mix. Even moderate consumption (two standard drinks) combined with sildenafil produces measurable additional blood pressure reduction [2]. Adding alprostadil to that scenario creates an unacceptable risk profile.

Alpha-blocker interactions compound the problem. If a patient is also taking tamsulosin, doxazosin, or another alpha-1 antagonist for benign prostatic hyperplasia, the blood pressure floor drops even lower. The sildenafil label specifically warns about orthostatic hypotension with concomitant alpha-blocker use, recommending a 4-hour dosing separation and initiation of sildenafil at 25 mg [2]. Adding alprostadil on top of an alpha-blocker plus PDE5 inhibitor regimen is generally considered too risky to attempt.

What About Other PDE5 Inhibitors?

The pharmacodynamic interaction with alprostadil applies to the entire PDE5 inhibitor class, not just sildenafil. Tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra) all increase cGMP by the same mechanism and carry the same additive vasodilation risk when combined with alprostadil [12].

Tadalafil deserves special mention because of its long half-life (17.5 hours, compared to 3-5 hours for sildenafil). The window during which additive effects persist is substantially longer with tadalafil. A patient who takes tadalafil 5 mg daily for BPH/ED and then uses intracavernosal alprostadil has a persistent baseline of PDE5 inhibition at all times. This makes dose titration of alprostadil more complex and arguably more dangerous. The blood pressure nadir from the combination may not be as sharp, but it is sustained [12].

The interaction severity ratings are identical across the PDE5 class in all major databases.

The CYP3A4 Wrinkle: Not the Primary Risk, but Worth Knowing

While the alprostadil-sildenafil interaction is pharmacodynamic, prescribers should remember that sildenafil plasma levels can be increased by strong CYP3A4 inhibitors. If a patient on combination alprostadil-sildenafil therapy also takes ketoconazole, itraconazole, ritonavir, or clarithromycin, sildenafil exposure increases substantially (ritonavir increased sildenafil AUC by 1,100% in a pharmacokinetic study) [2]. Higher sildenafil levels mean greater vasodilation, meaning the additive risk with alprostadil intensifies beyond what the dose alone would predict.

Grapefruit juice, a moderate CYP3A4 inhibitor, should also be avoided on dosing days.

Alprostadil itself has no meaningful CYP interactions because it bypasses hepatic metabolism entirely. Its rapid pulmonary clearance (plasma half-life of approximately 30 seconds for the free acid, 8-10 minutes for its primary metabolite 15-keto-PGE1) means it does not linger in circulation long enough for metabolic drug interactions to matter [1].

Bottom Line for Patients

Do not combine alprostadil and sildenafil on your own. The interaction is classified as major by every drug interaction database, and both FDA labels warn against unsupervised combination use. If you have tried both medications separately and neither works adequately alone, a urologist specializing in erectile dysfunction can evaluate whether supervised combination therapy is appropriate for your specific situation. The combination has documented efficacy in refractory cases, but it requires dose reduction, in-office first-dose testing, blood pressure monitoring, and clear priapism action plans.